Antidepressant showed no clear difference in improvement in depression: HAM‐D score at 6‐12 weeks (dichotomized) compared with placebo (low certainty).
Antidepressant showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with placebo (low certainty).
Antidepressant showed no clear difference in study dropouts at 6‐12 weeks compared with placebo (moderate certainty).
It is very uncertain whether antidepressant changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with placebo (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
The review found no eligible studies for this question.
Selective serotonin reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).
Selective serotonin reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).
Selective serotonin reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).
Selective serotonin reuptake inhibitors probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Serotonin‐norepinephrine reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).
Serotonin‐norepinephrine reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).
Serotonin‐norepinephrine reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).
Serotonin‐norepinephrine reuptake inhibitors showed no clear difference in number of dropouts due to adverse effects compared with placebo (moderate certainty).